Skip to main
  1. Stocks
  2. Biodesix Inc
  3. Forecast
BDSX

Biodesix Inc (BDSX) Stock Forecast & Price Target

Biodesix Inc (BDSX) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Biodesix is benefiting from a rebuilding sales force, stronger physician acquisition trends, and early signs that its Nodify lung-nodule franchise is gaining durable adoption, especially as CDT utilization rises and reimbursement improves. Its 2Q26 results reinforce the thesis: revenue grew 34.2% to $26.9M, diagnostic testing revenue rose 41.6% on 20,900 tests, gross margin expanded to 82%, and the adjusted EBITDA loss narrowed 56% to $3.2M, suggesting operating leverage is improving. The long-term outlook is further supported by a differentiated MRD strategy spanning both tumor-informed and tumor-naïve approaches, plus scalable health-system implementations that could deepen account penetration and broaden future growth.

Bears say

Biodesix is facing a cautious outlook because its Development Services pipeline is being pushed into 2027, limiting near-term revenue visibility despite contracted business rising only modestly to $8.7M from about $8.5M at 2Q-end. Management’s expectation of roughly $1M of Development Services revenue in 4Q and a 7–8% contribution of total revenue next year implies a slow recognition schedule, with study starts and sample shipments still gating conversion. Financial flexibility also looks tight, as it ended June 2026 with $30.0M in cash versus $50.0M in debt and posted ($1.6M) in operating cash flow during 2Q26, suggesting additional capital may be needed within the next 12 months.

Biodesix Inc (BDSX) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biodesix Inc and is not a guaranteed prediction by Public.com or investment advice.

Biodesix Inc (BDSX) Analyst Forecast & Price Prediction

Get the latest Biodesix Inc (BDSX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Biodesix Inc (BDSX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biodesix Inc (BDSX) Forecast

Analysts have given Biodesix Inc (BDSX) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Biodesix Inc (BDSX) has a Strong Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biodesix Inc (BDSX)


Biodesix Inc (BDSX) Analyst Forecast & Price Prediction

Get the latest Biodesix Inc (BDSX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Biodesix Inc (BDSX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover BDSX stock data and trends